Biological therapy for maintenance management of Crohn disease

For luminal or fistulising Crohn disease that is refractory to the above therapy, biological therapy (a tumour necrosis factor [TNF] inhibitor [eg adalimumab, infliximab], interleukin inhibitor [eg ustekinumab], or anti-integrin antibody [eg vedolizumab]) is effective for maintaining remission if there was a response to induction therapy with these drugs; refer to a gastroenterologist.